Core Viewpoint - Cognition Therapeutics, Inc. is making significant progress in its clinical programs for neurodegenerative disorders, particularly Alzheimer's disease and dementia with Lewy bodies, and is preparing for key presentations and regulatory meetings in early 2025 [2][3]. Company Developments - CEO Lisa Ricciardi will participate in conferences during the JP Morgan Healthcare Conference week to discuss advancements made in 2024 [1][2]. - The company achieved positive topline results from its Phase 2 SHIMMER study in patients with dementia with Lewy bodies, with findings to be presented at the International Lewy Body Dementia Conference in January 2025 [2]. - Cognition Therapeutics is preparing for an end-of-Phase 2 meeting with the FDA to review results from its SHINE study in mild-to-moderate Alzheimer's disease, marking an important regulatory milestone [2]. - The company received clearance for the generic name of its candidate, CT1812, which will be known as zervimesine [2]. Upcoming Events - Cognition Therapeutics will present at the Longwood Healthcare Leaders Stanford Summit on January 11, 2025, and at the Sachs 8th Annual Neuroscience Innovation Forum on January 12, 2025 [3]. - The panel discussions will focus on accelerating drug development and innovations in Alzheimer's disease and other cognitive disorders [3]. Company Overview - Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics for age-related degenerative disorders of the central nervous system and retina [3]. - The lead candidate, zervimesine, is being investigated in clinical programs for Alzheimer's disease, dementia with Lewy bodies, and dry age-related macular degeneration [3]. - The company believes that zervimesine and its pipeline of Ï-2 receptor modulators can effectively regulate impaired pathways in these diseases, offering a distinct approach compared to other treatments [3].
Cognition Therapeutics CEO Participating in Longwood and Sachs Conferences